ABLYNX DEMONSTRATES BIOEQUIVALENCE BETWEEN LIQUID AND

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
ABLYNX DEMONSTRATES BIOEQUIVALENCE BETWEEN LIQUID AND LYOPHILISED FORMULATIONS OF ITS ANTI-vWF NANOBODY, CAPLACIZUMAB

Caplacizumab has first-in-class potential for the treatment of thrombotic thrombocytopenic purpura (TTP)

On track to start Phase III study in patients with acquired TTP in mid-2015

GHENT, Belgium, Nov. 26, 2014 (GLOBE NEWSWIRE) -- Ablynx [Euronext Brussels: ABLX] today announced positive results from the Phase I trial to demonstrate bioequivalence between the liquid and lyophilised formulations of caplacizumab, Ablynx's anti-von Willebrand factor Nanobody developed for the treatment of acquired TTP.

The liquid formulation has been used in clinical trials to date but the lyophilised form is more stable and can be stored and transported at 5°C, which is much more convenient than the liquid formulation, which has to be stored and shipped frozen. The lyophilised form will now be used in the forthcoming Phase III trial and would be the formulation of choice for commercialisation.

The Phase I trial involved a single-centre, open-label, randomised, single dose cross-over study in 24 healthy male subjects to evaluate the bioequivalence and tolerability of liquid and reconstituted lyophilised formulations of caplacizumab administered subcutaneously. The bioequivalence criteria were based on the evaluation of the "area under the plasma concentration versus time curve (AUC)" and the "maximum observed plasma concentration (C max )".

The results from this study demonstrate that the lyophilised and liquid formulations of caplacizumab administered subcutaneously are bioequivalent based on the pharmacokinetic parameters as described above. In addition, both formulations were well tolerated and no treatment emergent serious adverse events were reported.

Dr Edwin Moses, CEO of Ablynx, commented:

"We are very pleased to show bioequivalence between the liquid and lyophilised formulations of caplacizumab, which is a very important milestone in the development of the product. We believe that this lyophilised form has a number of advantages and will allow for convenient self-administration in the home setting. We are on track to starting the Phase III study with this new lyophilised formulation in patients with acquired TTP in mid-2015."

About caplacizumab

Caplacizumab is a bivalent anti-vWF Nanobody which is highly potent and selective. It received Orphan Drug Designation in the US and EU in 2009 and could be the first drug specifically approved for the treatment of acquired TTP as an adjunct to plasma exchange and immunosuppressants. Efficacy and safety were demonstrated for caplacizumab in a worldwide Phase II study in patients with acquired TTP, demonstrating that it could act as a protective agent in the acute phase of the disease, preventing microthrombi and having the potential to reduce morbidity due to organ damage as well as preventing exacerbations. In addition, in this Phase II study, caplacizumab was generally well-tolerated and had a manageable bleeding side effect profile.

Von Willebrand factor (vWF) is a blood glycoprotein involved in haemostasis, a complex process that causes the bleeding process to stop. vWF's primary function is to bind to other proteins, including glycoprotein Ib in the initiation of platelet adhesion. vWF is implicated in TTP where ultra-large, multimeric precursors of vWF (UL-vWF) are present in the blood of patients leading to unwanted blood clot formation. UL-vWF can readily bind platelets leading to the formation of characteristic string-like clots in small blood vessels. Caplacizumab inhibits platelet binding to UL-vWF and thus has the potential to prevent the formation of these string-like clots in the blood of patients with acquired TTP.

About thrombotic thrombocytopenic purpura (TTP)

TTP is a rare disorder of the blood coagulation system that causes extensive microscopic thromboses in small blood vessels throughout the body. It is a potentially life-threatening disorder characterised by thrombocytopenia, haemolytic anaemia and microvascular thrombosis causing variable degrees of tissue ischemia and infarction. TTP exists in two forms: a congenital and an acquired form, with the latter accounting for >90% of the patients. There are currently no drugs specifically approved for the treatment of TTP. The standard of care for the acquired form of TTP is multiple daily plasma exchanges until confirmed platelet normalisation which occurs when the patient's platelet count returns to normal. This treatment requires lengthy hospital stays and may be associated with clinical complications. Additionally, a significant number of patients will subsequently suffer either an exacerbation of the TTP episode or a later relapse after recovering from a first TTP episode. There are believed to be approximately 10,000 TTP-related events in the US and top 15 European markets per year.

About Ablynx

Ablynx is a biopharmaceutical company engaged in the development of Nanobodies® , proprietary therapeutic proteins based on single-domain antibody fragments, which combine the advantages of conventional antibody drugs with some of the features of small-molecule drugs. Ablynx is dedicated to creating new medicines which will make a real difference to society. Today, the Company has more than 30 proprietary and partnered programmes in development in therapeutic areas including inflammation, haematology, oncology and respiratory disease. The Company has collaborations and significant partnerships with pharmaceutical companies including AbbVie, Boehringer Ingelheim, Merck & Co, Merck Serono and Novartis. The Company is headquartered in Ghent, Belgium. More information can be found on www.ablynx.com .

For more information, please contact

Ablynx:

Dr Edwin Moses
CEO
t:   +32 (0)9 262 00 07
m: +44 (0)7771 954 193 /
     +32 (0)473 39 50 68
e:  edwin.moses@ablynx.com

Marieke Vermeersch
Associate Director Investor Relations
t:   +32 (0)9 262 00 82
m: +32 (0)479 49 06 03
e:  marieke.vermeersch@ablynx.com
Follow us on Twitter @AblynxABLX

Ablynx media relations Consilium Strategic Communications:

Mary-Jane Elliott, Jonathan Birt, Amber Bielecka, Lindsey Neville
t:   +44 203 709 5700
e:  ablynx@consilium-comms.com

pdf format of the press release http://hugin.info/137912/R/1874299/660278.pdf

HUG#1874299

Scroll down for more posts ▼

Top 10 Most Recent News Articles

RayNeo's Black Friday Push Tests Smart Glasses Demand

Updated Category News Views 176

A million shipped pairs is a real milestone, but holiday markdowns are where the rubber meets the road for RayNeo. The company is taking its XR gaming glasses and iO AI smart glasses into Europe’s Black Friday scrum with discounts running through late November, betting that portability, giant virtual screens and a little AI convenience can pry open consumers’ wallets....

Continue Reading
Chemours Legal Succession Gets a Long Transition Runway

Updated Category News Views 85

A corporate-law handoff rarely sets pulses racing, but this one deserves a proper look. Chemours is replacing its long-serving general counsel while keeping the departing executive in the building for four additional months. That is not flashy, and thank goodness for that. In a global chemicals company, legal leadership touches regulation, compliance, governance,...

Continue Reading
Hone Health’s $228M Bet on Data-Led Longevity Care

Updated Category News Views 230

Longevity medicine just got a very large check and an even larger assignment. Hone Health says it has raised $228 million to push physician-led care beyond its roots in hormone optimization, and the split of that financing matters more than the celebrity names attached to it. Only $28 million is described as Series A equity; the other $200 million comes as growth...

Continue Reading
Century Complete Tests Conway Demand Near Myrtle Beach

Updated Category News Views 108

Ninety-four lots in Conway may not move Wall Street by themselves, but they can say plenty about the kind of buyer Century Communities is chasing. Century Complete is opening its model at Cates Bay Crossing on Nov. 21, 2026, with single-family homes starting in the $260s. In a housing market where affordability gets talked to death and rarely delivered cleanly, that...

Continue Reading
Resolve Adds Cahaba in Birmingham Pain-Care Expansion

Updated Category News Views 198

Pain-care consolidation has a peculiar way of looking tidy in a release and messy in the real world. Resolve Pain Solutions announced on November 18, 2026, that it has acquired Cahaba Pain and Spine Care, an established provider serving greater Birmingham, Alabama. On its face, this is a straightforward expansion move: buy a respected local practice, retain its physician...

Continue Reading
Pacific Surfliner Faces Thanksgiving Capacity Test

Updated Category News Views 122

Thanksgiving traffic on Southern California freeways is its own yearly punishment, and the Pacific Surfliner is making a sensible pitch: leave the car parked and let the coast roll past the window. For travelers, that can be a real relief. For anyone watching public transportation, this is also a useful little stress test of whether a busy state-supported rail corridor...

Continue Reading
WYBOT's New Robots Push Hands-Free Pool Care in Lyon

Updated Category News Views 77

A pool robot climbing out of the water to dock itself is the sort of demo that makes people stop mid-aisle at a trade show. WYBOT brought precisely that kind of attention-grabber to Piscine Global Lyon 2026, running November 17–20 at Eurexpo Lyon. The company is showing a broader lineup, but the M3 Pro is plainly the headline act: WYBOT calls it the world's first...

Continue Reading
illumine Targets Childcare Chain Control and Risk Gaps

Updated Category News Views 131

Expansion Gets Messy Before It Gets Impressive Childcare operators do not usually stumble because they forgot how to care for children; they stumble because the back office fractures as the network grows. One center handles fees one way, another lets enrollment leads work a different funnel, and headquarters discovers too late that its reports are arguing with each other....

Continue Reading
Modexus Opens a $500 Million Buyback With Real Caveats

Updated Category News Views 155

A half-billion-dollar buyback authorization can make a stock crowd sit up fast, and Modexus Solutions has plainly chosen that moment. On November 18, 2026, the Racine, Wisconsin-based thermal-management company said its board authorized repurchases of up to $500 million of common stock. For holders of NYSE:MOD, that is a meaningful declaration of intent. It says...

Continue Reading
Precision Metal Forming Is Industry's Quiet Backbone

Updated Category News Views 205

A fraction of a millimeter can turn a perfectly good industrial part into an expensive headache. That unglamorous reality sits at the center of Michele Caulfield's discussion of precision metal forming for HelloNation, and it deserves more attention than it usually gets. Investors watching manufacturing tend to chase flashy automation headlines, big aerospace orders, or...

Continue Reading

Top 5 Most Recently Viewed Articles

Honda Motor Co. Reports Strong Q1 Results Amid Challenges

Updated Category News Views 247

Honda Motor Co.'s Recent Financial Outcomes Honda Motor Co., Ltd. has reported its consolidated financial results for the fiscal first quarter, which concluded on June 30, 2025. This announcement highlights the company’s financial performance amidst a challenging economic landscape. Analysts and stakeholders are keen to understand how these results impact future...

Continue Reading
Transforming Education: Launch of ArthurAI by MindHYVE.ai™

Updated Category News Views 199

MindHYVE.ai™ and TechMindset Africa Unveil ArthurAI MindHYVE.ai™ and TechMindset Africa recently marked a significant moment by launching ArthurAI, a pioneering AGI-powered education platform. This innovative initiative embodies their commitment to transforming the educational landscape throughout the African continent. Strategic Partnership for Education The launch...

Continue Reading
Metagenomi Insiders Under Fire: Shareholder Concerns

Updated Category News Views 71

Unpacking the Heat at Metagenomi Picture this—you're sitting on the edge of your investment seat, holding stock in Metagenomi Therapeutics, Inc. (NASDAQ:MGX), and suddenly, there's a bombshell. Halper Sadeh LLC, an outfit that's no stranger to rattling corporate cages, has its sights set on whether the bigwigs at Metagenomi breached their fiduciary duties. Now, if...

Continue Reading
KBR Inc. Unveils Bold Spin-Off Strategy for Growth

Updated Category News Views 302

KBR Inc. Unveils Its Plan to Spin Off Mission Technology Solutions KBR, Inc. announced that its board of directors has adopted a comprehensive strategy to spin off its Mission Technology Solutions business. This significant move aims to separate the company into two distinct public entities, which is expected to be realized in a tax-free transaction targeted for...

Continue Reading
Waters Corporation Plans Upcoming Earnings Call for Q3 2025

Updated Category News Views 198

Waters Corporation Announces Q3 2025 Earnings Conference Call Waters Corporation (NYSE: WAT) is set to hold an important conference call aimed at discussing its financial results for the third quarter of 2025. This event is scheduled for early November. The company has a strong reputation for transparency and is committed to engaging with its investors. Details of the...

Continue Reading